Verallo, Jann Ciel P.
HRN: 26-90-18 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/31/2025
OXACILLIN 500MG (VIAL)
03/31/2025
04/06/2025
IV
250
Q6
Staphylococcal Skin Infection
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes